Business● Low31m ago · Nov 21, 2026, 12:25 PM
Capricor reviewing operations as FDA rejects cell therapy
GlobeAlert Desk · curated from Seeking Alpha Tech · North America
Capricor is reviewing its operations after the FDA rejected its cell therapy product. This signifies a significant regulatory and business setback for the company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
North America theater · last 7 days
rising · 31 in the last 24h1,526
events logged
97
risk index / 100
Wildfires 600Attacks & Assaults 453Robberies & Theft 184Shootings 177Rocket Launches 37
- Protest activity (117 reports)Protests · United States · 11m ago
- Conflict activity (155 reports)Conflict Events · United States · 11m ago
- Cyber activity (173 reports)Cyber Threats · United States · 25m ago
More in Business
Business22m agoIllia highway closed for works during the long weekend: how it will affect trafficInfobae · ArgentinaBusiness28m agoEU budget: Costa pitches more cuts, Big Tech tax to break deadlockEuroNews [en]Business30m agoTax reform requires invoices for rentals, flights, and real estate in 2027Folha de S.Paulo · BrazilBusiness56m agoPartners back Real Madrid's accounts, with record revenues of 1,221 millionInfobae · Argentina